Why the study?
Is apixaban cost-effective compared to dabigatran and rivaroxaban for stroke prevention in patients with atrial fibrillation?
Is apixaban cost-effective compared to dabigatran and rivaroxaban for stroke prevention in patients with atrial fibrillation?
Based on indirect comparisons and Markov modeling, apixaban is projected to be a cost-effective alternative to dabigatran and rivaroxaban for stroke prevention in atrial fibrillation from the UK NHS perspective.
No takes yet. Share an insight, caveat, or question.
Apixaban may appear cost-effective versus other NOACs in UK AF modeling; leaves open validation with direct trials and real-world data.
Lip et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: